Innovative Chronic Pain Treatment Receives allowance for IP Protection in Japan’s World Third Largest Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Oct. 15, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” […]
This is the second successful treatment in a donkey, demonstrating the potential of Innocan’s Liposomal CBD injection for human and veterinary use HERZLIYA, Israel and CALGARY, AB, Feb. 10, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: […]
HERZLIYA, Israel and CALGARY, AB, Nov. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive […]
HERZLIYA, Israel and Calgary, AB, Oct. 16, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in chronic pain management via Liposomal CBD drug products, is pleased […]
HERZLIYA, Israel and CALGARY, Alberta, Oct. 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce promising […]
